NCT01649635View on ClinicalTrials.gov

Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer

PHASE4CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

January 31, 2014

Study Completion Date

June 30, 2016

Conditions
Prostate Cancer
Interventions
DRUG

CABAZITAXEL (XRP6258)

Pharmaceutical form: solution Route of administration: intravenous

DRUG

Prednisone

Pharmaceutical form: tablet Route of administration: oral

DRUG

Ciprofloxacin

Pharmaceutical form: tablet Route of administration: oral

DRUG

G-CSF (Granulocyte colony-stimulating factor)

Pharmaceutical form: solution Route of administration: subcutaneous

Trial Locations (6)

78020-400

Investigational Site Number 007, Centro

81520-060

Investigational Site Number 004, Curitiba

95900-000

Investigational Site Number 006, Lajeado

90035-903

Investigational Site Number 005, Porto Alegre

09050-360

Investigational Site Number 001, Santo André

01321-001

Investigational Site Number 002, São Paulo

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY

NCT01649635 - Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer | Biotech Hunter | Biotech Hunter